

RESULTS OF ANNUAL GENERAL MEETING

Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, 'Aroa' or the 'Company') advises that in accordance with Listing Rule 3.13.2, details of the resolutions and the proxies received in respect of each resolution are set out in the attached summary.

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About AROA™

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. AROA's products have been used in more than four and a half million procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX). www.aroabio.com

Contacts

Investor

Simon Hinsley
Investor Relations
shinsley@aroabio.com
+ 61 401 809 653

Media

Australia

Matthew Wright
matt@nwrcommunications.com.au
+61 451 896 420

New Zealand

Piet De Jong
piet.dejong@baldwinboyle.com
+64 21 812 766

Resolution Details			Show of Hands or Poll	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Res. Results
Resolution		Res. Type	S or P	For	Against	Proxy's Discretion	Abstain/ Excluded	For	Against	Abstain*	Carried / Not Carried
1	Re-election of James McLean as a Director	Ordinary	P	177,385,027 97.99%	2,561,653 1.42%	1,071,849 0.59%	38,168 -	181,940,329 98.61%	2,561,653 1.39%	38,168 -	Carried
2	Re-election of Steven Engle as a Director	Ordinary	P	167,361,388 92.46%	12,585,292 6.95%	1,071,849 0.59%	38,168 -	171,896,690 93.18%	12,585,292 6.82%	78,168 -	Carried
3	Auditor's Remuneration	Ordinary	P	179,885,262 99.38%	61,418 0.03%	1,070,899 0.59%	39,118 -	184,273,139 99.97%	61,418 0.03%	226,543 -	Carried
4	Grant of share options to James McLean	Ordinary	P	106,411,896 86.87%	14,988,711 12.24%	1,085,875 0.89%	58,570,215 -	110,579,840 87.88%	15,255,444 12.12%	58,710,840 -	Carried
5	Grant of share options to Steven Engle	Ordinary	P	91,989,200 75.10%	29,420,433 24.02%	1,076,849 0.88%	58,570,215 -	96,117,144 76.40%	29,687,166 23.60%	58,750,840 -	Carried
6	Grant of share options to Philip McCaw	Ordinary	P	92,024,538 75.12%	29,395,398 24.00%	1,076,849 0.88%	58,559,912 -	96,192,482 76.43%	29,662,131 23.57%	58,700,537 -	Carried
7	Grant of share options to John Pinion	Ordinary	P	91,987,400 75.10%	29,420,433 24.02%	1,076,849 0.88%	58,572,015 -	96,155,344 76.41%	29,687,166 23.59%	58,712,640 -	Carried
8	Grant of share options to John Diddams	Ordinary	P	91,816,207 75.06%	29,427,001 24.05%	1,088,952 0.89%	58,724,537 -	95,984,151 76.37%	29,693,734 23.63%	58,865,162 -	Carried
9	Grant of 2022 LTI share options to Brian Ward	Ordinary	P	107,495,525 87.76%	13,912,308 11.36%	1,076,849 0.88%	58,572,015 -	111,679,894 88.73%	14,179,041 11.27%	58,696,215 -	Carried
10	Grant of 2023 LTI share options to Brian Ward	Ordinary	P	118,590,908 96.81%	2,829,028 2.31%	1,076,849 0.88%	58,559,912 -	122,775,277 97.54%	3,095,761 2.46%	58,684,112 -	Carried